Therefore, there is a potential therapeutic benefit for targeting BDNF in MCs for neuroprotection, which will not only be important generally for treating neuronal degeneration in DR, AMD, and other hypoxic retinal diseases, but will also be particularly useful in dealing with the potential retinal degeneration reported in patients with long-term anti-VEGF therapies [16,19]. This evidence concerns the gene VEGFA and Abnormal retinal morphology.